053950 — Kyung Nam Pharm Co Share Price
Last trade - 00:00- KR₩51bn
- KR₩38bn
- KR₩61bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.45 | ||
| Price to Tang. Book | 0.46 | ||
| Price to Free Cashflow | 304.16 | ||
| Price to Sales | 0.86 | ||
| EV to EBITDA | 23.72 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -0.52% | ||
| Return on Equity | -4.2% | ||
| Operating Margin | -1.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 70,946.53 | 64,623.47 | 59,000.42 | 59,303.48 | 60,792.07 | n/a | n/a | 6.29% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
KYUNG NAM PHARM.CO., LTD. is a Korea-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company's product portfolio consists of vitamin products, placenta products, health food products and general pharmaceuticals. The Company provides vitamin products under the brand name LEMONA. It supplies health food products such as lactobacillus products through convenient stores and marts. The placenta products include human placenta related injections and drinks. The general pharmaceuticals include athlete foot therapeutic agents, inflammatory drugs, cold remedies, multi-nutrients and others.
Directors
- Geon Wu Bae CEO (58)
- Eun Huh MDR (53)
- Byeong Seop Hwang OTH (48)
- Chang Ju Lee DRC (41)
- Cheol Min Kang DRC (42)
- Byeong Jin Kim DRC (42)
- Yong Lee DRC (49)
- Su Jin Oh DRC (43)
- Cheol Choi NID (40)
- Jae Deok Gwon NID (53)
- Jae Hun Kim NID (51)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 29th, 1998
- Public Since
- November 6th, 2001
- No. of Shareholders
- 25,637
- No. of Employees
- 215
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 78,147,071
- Address
- 79, Guryong-ro 4nam-gil, Uiryeong-eup, UIRYEONG, 52153
- Web
- https://www.kyungnampharm.com:6519/
- Phone
- +82 234905105
- Auditors
- Deloitte Anjin LLC
Upcoming Events for 053950
Similar to 053950
AbClon
Korea Exchange - KOSDAQ
ADBiotech Co
Korea Exchange - KOSDAQ
AHN-GOOK PHARMACEUTICAL Co
Korea Exchange - KOSDAQ
Alteogen
Korea Exchange - KOSDAQ
Aminologics Co
Korea Exchange - KOSDAQ
FAQ
As of Today at 21:41 UTC, shares in Kyung Nam Pharm Co are trading at KR₩669. This share price information is delayed by 15 minutes.
Shares in Kyung Nam Pharm Co last closed at KR₩669 and the price had moved by -30.26% over the past 365 days. In terms of relative price strength the Kyung Nam Pharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -29.46% over the past year.
There is no consensus recommendation for this security.
Find out moreKyung Nam Pharm Co does not currently pay a dividend.
Kyung Nam Pharm Co does not currently pay a dividend.
Kyung Nam Pharm Co does not currently pay a dividend.
To buy shares in Kyung Nam Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of KR₩669, shares in Kyung Nam Pharm Co had a market capitalisation of KR₩51bn.
Here are the trading details for Kyung Nam Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 053950
Based on an overall assessment of its quality, value and momentum Kyung Nam Pharm Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Kyung Nam Pharm Co is KR₩661. That is 1.22% below the last closing price of KR₩669.
Analysts covering Kyung Nam Pharm Co currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kyung Nam Pharm Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +10.25%.
As of the last closing price of KR₩669, shares in Kyung Nam Pharm Co were trading -10.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Kyung Nam Pharm Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩669.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Kyung Nam Pharm Co's management team is headed by:
- Geon Wu Bae - CEO
- Eun Huh - MDR
- Byeong Seop Hwang - OTH
- Chang Ju Lee - DRC
- Cheol Min Kang - DRC
- Byeong Jin Kim - DRC
- Yong Lee - DRC
- Su Jin Oh - DRC
- Cheol Choi - NID
- Jae Deok Gwon - NID
- Jae Hun Kim - NID